The advancement of HMBD-001 in clinical development demonstrates translation of Hummingbird Bioscience’s AIMM platform from drug design through clinical development and patient selection
Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, has won the Asia Pacific Trailblazer Award at the 2026 AI Discovery Awards hosted by Nebius.
Hummingbird Bioscience today announced that the first patient has been dosed in a Phase I clinical trial of HMBD-501 for the treatment of patients with advanced HER3-expressing solid malignancies
